TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06643884: A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid

Sponsor: Aura Biosciences · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$554,400

Rescue Site Savings

+$369,600

Unlock Full NCT06643884 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06643884 Rescue Dossier →